Mark Hahn - Sep 26, 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Sep 26, 2022
Transactions value $
$0
Form type
4
Date filed
9/28/2022, 04:06 PM
Previous filing
Aug 11, 2022
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Award $0 +3.6M +25.15% $0.00 17.9M Sep 26, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 900,000 RSUs vesting on November 1, 2023 and the balance vesting in 12 equal quarterly installments thereafter.
F3 Consists of (i) 10,602,376 Ordinary Shares underlying RSUs (which are represented by 1,325,297 ADSs); and (ii) 7,311,120 Ordinary Shares underlying 913,890 ADSs.